Chemo-immunotherapy after surgery for early reoccurring nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at whether adding chemo-immunotherapy after surgery is better than surgery alone for patients whose nasopharyngeal cancer has returned but is still in early stages. It may help prevent the cancer from coming back again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal cancer that has come back (recurrent).
- Your cancer is at an early stage (rT1, rT2 with specific features, or rT3 limited to the sphenoid sinus bottom).
- You are between 18 and 75 years old.
- Your last radiation treatment was at least 6 months ago, and you have only had one course of radiation.
- You have had surgery to remove the cancer and the surgical margins were clear (no cancer cells at the edge).
- You are in reasonably good health (ECOG score 0-2) and your organs are working well enough to handle chemo and immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
This trial tests if careful monitoring after a combination of immunotherapy and chemotherapy is a safe and effective approach for patients whose nasopharyngeal cancer has come back but not spread to other parts of the body. It aims to reduce unnecessary treatment while keeping the cancer under control.
This study compares two treatments—surgery or IMRT (a targeted type of radiation)—for early-stage cancer that has come back in the nasopharynx without spreading. It aims to see which approach works better and is safest for people in your situation.
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
This trial tests a chemotherapy combination (TC) given after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this treatment helps prevent the cancer from returning again.
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.